Genmab Phase 2 Trial Shows Durable Responses in Resistant Ovarian Cancer
Genmab's rinatabart sesutecan met key endpoints in a Phase 2 study targeting platinum-resistant ovarian cancer, a difficult-to-treat disease.
Genmab announced results from its Phase 2 RAINFOL-01 clinical trial evaluating rinatabart sesutecan, also known as Rina-S, in patients with platinum-resistant ovarian cancer, a form of the disease that has historically offered few effective treatment options.
The trial data indicated that the experimental therapy produced durable and clinically meaningful responses among participants, according to the company's media release. Platinum-resistant ovarian cancer is considered particularly challenging to treat because it has stopped responding to standard platinum-based chemotherapy regimens.
Read more Xryma Plc Reports Resignation of Independent Non-Executive Directors →
Rinatabart sesutecan is an antibody-drug conjugate, a class of targeted therapies that pair a monoclonal antibody with a cancer-killing agent designed to deliver treatment directly to tumor cells. The RAINFOL-01 designation reflects the trial's focus on folate receptor-targeting, a mechanism relevant to ovarian cancer biology.
The results add to a growing body of evidence surrounding next-generation antibody-drug conjugates in gynecologic oncology, a therapeutic area that has attracted significant research investment in recent years. Clinical durability of response is a key benchmark in this setting, as patients with platinum-resistant disease often experience rapid progression on available treatments.
Full details of the RAINFOL-01 data, including response rates and safety profiles, were disclosed in Genmab's official release. Continue reading at GlobeNewswire - Industry News on Financial Services.
